论文部分内容阅读
目的探讨小剂量尿激酶并尼莫地平治疗急性脑梗死患者的安全性和有效性。方法选择发病6~72h的急性脑梗死患者120例,随机分为对照组、尿激酶组和尼莫地平组各40例,全部患者均给予常规治疗,尿激酶组还给予尿激酶治疗,尼莫地平组还给予尿激酶+尼莫地平治疗,并于治疗前和治疗后14、30d采用BI量表及治疗前和治疗后90d采用mRS量表评价患者神经功能。结果治疗后14、30d尿激酶组的BI评分明显优于对照组(P<0.05),尼莫地平组与对照组比较则有显著性差异(P<0.01),且明显优于尿激酶组(P<0.05);治疗后90dmRS量表评价尿激酶组、尼莫地平组分别与对照组比较有显著性差异(P<0.01),且尼莫地平组与尿激酶组比较也有显著性差异(P<0.01)。结论小剂量尿激酶合用尼莫地平治疗可以有效地改善急性脑梗死患者的神经功能缺损,提高生活能力,改善生活质量,且安全性较好。
Objective To investigate the safety and efficacy of low-dose urokinase combined with nimodipine in patients with acute cerebral infarction. Methods A total of 120 acute cerebral infarction patients from 6 to 72 hours after onset were randomly divided into control group, urokinase group and nimodipine group. All patients were given conventional therapy. Urokinase group was given urokinase treatment, Hepatic group also given urokinase + nimodipine treatment, and in the pre-treatment and post-treatment 14,30 d using the BI scale before treatment and 90 d after treatment using mRS scale evaluation of neurological function. Results The BI score of urokinase group was significantly better than that of the control group (P <0.05) at 14 and 30 days after treatment, and there was significant difference between the nimodipine and control groups (P <0.01) P <0.05). After 90dmRS treatment, there was significant difference between Urokinase group and Nimodipine group (P <0.01), and there was significant difference between Nimodipine group and Urokinase group (P <0.01). Conclusions The combination of low-dose urokinase and nimodipine can effectively improve the neurological deficits, improve the quality of life and improve the quality of life in patients with acute cerebral infarction.